Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 2Urinary Bladder Neoplasms 1Turcot syndrome 1Stomach Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphatic Metastasis 1Lung Neoplasms 1Head and Neck Carcinoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Cancer Patients 1

Interventions

Gemcitabine 406Oxaliplatin 131Fluorouracil 125130-nm albumin-bound paclitaxel 108Capecitabine 100Albumin-Bound Paclitaxel 90Leucovorin 88Irinotecan 87Radiotherapy 76Radiosurgery 64Taxes 63Cisplatin 56Erlotinib Hydrochloride 44Drug Therapy 42folfirinox 40Magnetic Resonance Spectroscopy 39pembrolizumab 35Blood Specimen Collection 33S 1 (combination) 31Pancreaticoduodenectomy 31Docetaxel 31Nivolumab 30Bevacizumab 30Biopsy 26Surgical Procedures, Operative 25Cyclophosphamide 25irinotecan sucrosofate 24Specimen Handling 24Radiation 22Standard of Care 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Pancreatic Neoplasms × DEAE-Dextran × Clear all
NCT07595172 2026-05-19

NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer

West China Hospital

Phase 1/2 Recruiting
55 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06359275 2024-06-25

PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients

Fudan University

Phase 2 Recruiting
81 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡